
Ascendis Pharma A/S: updates and filings
Price
$270.33
November 18, 2026Market cap $16.4B
What Ploutos Investor adds for Ascendis Pharma A/S
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2015
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Current report (foreign company)Form6-K
- Nov 12, 2026Current report (foreign company)Form6-K
- Nov 12, 2026Current report (foreign company)Form6-K
- Nov 6, 2026Current report (foreign company)Form6-K
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 26, 2026Current report (foreign company)Form6-K
- Oct 16, 2026Current report (foreign company)Form6-K
- Oct 14, 2026Current report (foreign company)Form6-K
- Sep 29, 2026Current report (foreign company)Form6-K
- Sep 15, 2026Current report (foreign company)Form6-K
- Sep 15, 2026Current report (foreign company)Form6-K
- Sep 9, 2026Current report (foreign company)Form6-K
- Sep 9, 2026Current report (foreign company)Form6-K
- Aug 31, 2026Current report (foreign company)Form6-K
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Current report (foreign company)Form6-K
- Aug 13, 2026Current report (foreign company)Form6-K
- Aug 12, 2026Current report (foreign company)Form6-K
- Aug 6, 2026Current report (foreign company)Form6-K
- Jul 15, 2026Current report (foreign company)Form6-K
- Jun 30, 2026Current report (foreign company)Form6-K
- Jun 29, 2026Current report (foreign company)Form6-K
- Jun 17, 2026Current report (foreign company)Form6-K
- Jun 15, 2026Current report (foreign company)Form6-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 6-K | Current report (foreign company) | Document |
| Nov 12, 2026 | 6-K | Current report (foreign company) | Document |
| Nov 12, 2026 | 6-K | Current report (foreign company) | Document |
| Nov 6, 2026 | 6-K | Current report (foreign company) | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 26, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 16, 2026 | 6-K | Current report (foreign company) | Document |
| Oct 14, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 29, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 15, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 15, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 9, 2026 | 6-K | Current report (foreign company) | Document |
| Sep 9, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 31, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 13, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 12, 2026 | 6-K | Current report (foreign company) | Document |
| Aug 6, 2026 | 6-K | Current report (foreign company) | Document |
| Jul 15, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 30, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 29, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 17, 2026 | 6-K | Current report (foreign company) | Document |
| Jun 15, 2026 | 6-K | Current report (foreign company) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 1, 2014.
The full analysis
What do Ascendis Pharma A/S's filings show?
The filings are where every one of Ascendis Pharma A/S's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.